Orchestra BioMed Holdings, Inc.: Form 10-K for the period ended Dec 31, 2024
Filed with the SEC on Mar 31, 2025 and accepted by EDGAR at Mar 31, 2025, 16:16 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2024-01-01 to 2024-12-31 | $2.6m | us-gaap:Revenues |
| Cost of revenue | 12 months2024-01-01 to 2024-12-31 | $204.0k | us-gaap:CostOfRevenue |
| Research and development | 12 months2024-01-01 to 2024-12-31 | $42.8m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2024-01-01 to 2024-12-31 | $23.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2024-01-01 to 2024-12-31 | −$64.3m | us-gaap:OperatingIncomeLoss |
| Net income | 12 months2024-01-01 to 2024-12-31 | −$61.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2024-01-01 to 2024-12-31 | −$1.66 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2024-01-01 to 2024-12-31 | −$1.66 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2024-01-01 to 2024-12-31 | 36,821,042 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2024-01-01 to 2024-12-31 | −$50.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2024-01-01 to 2024-12-31 | $289.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-12-31 | $22.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-12-31 | $69.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-12-31 | $76.2m | us-gaap:Assets |
| Current liabilities | At period end2024-12-31 | $16.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-12-31 | $43.2m | us-gaap:Liabilities |
| Long-term debt | At period end2024-12-31 | $15.0m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2024-12-31 | $33.0m | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |
Source: SEC EDGAR, the filing index for accession 0001558370-25-004161. Last ingested by Listed: Nov 2, 2026, 11:52 ET. Listed shows no prices and gives no investment advice.